Epilepsy, one of the most common diseases of the central nervous system affects about 65 million people worldwide and more than 2 million in the U.S. Anyone can develop epilepsy as it occurs across all ages, races, and genders.
UCB, www.ucb-usa.com, a global biopharmaceutical company is collaborating with Georgia Tech’s Interoperability, Integration, and Innovation Lab (I3L) http://i3l.gatech.edu to explore the potential for predictive analytics to help determine treatment decisions for people living with epilepsy.
UCB will contribute their expertise in epilepsy treatment and provide access to large sets of epilepsy data. The I3L will supply access to an extensive collection of health IT resources to provide critical data to EHR systems.
The ultimate goal of the partnership is to develop an interactive system able to convert large amounts of anonymous patient data into real-time insights so that providers will be able to consult at the point-of-care.
Last year, UCB completed a proof of concept study which explored using computer models to improve epilepsy treatment selection. Building on this proof of concept study, UCB and the I3L are now seeking a pathway to deliver these capabilities to clinics.
“The innovative nature of the project reflects UCB and the I3L Lab’s shared goal of delivering more patient-centric health solutions in Georgia and beyond,” said Mark Braunstein, MD., one of the I3L’s founders. “We believe that by arming physicians with insights to help them identify the best possible treatment options for people with epilepsy, we can help drive better patient outcomes and deliver a higher standard of epilepsy care.”